Consensus Palvella Therapeutics, Inc.

Stocks

PVLA

US6979471090

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 00:57:09 07/11/2026 +04			5-day change	1st Jan Change
173.82 ^USD	+10.82%		+19.23%	+66.48%

08:24pm	Oppenheimer Adjusts Palvella Therapeutics Price Target to $232 From $210, Maintains Outperform Rating	MT
11-05	Palvella Therapeutics Shares Drop After Q3 Net Loss Widens	MT

Evolution of the Average Target: Palvella Therapeutics, Inc.

Evolution of the Target Price: Palvella Therapeutics, Inc.

Changes in Analyst Recommendations: Palvella Therapeutics, Inc.

2b93cd98a21b8f.rZUQez3qwrmlqF1GolpmRcN5FNPsiYxeNqgSbYBiOnU.yORENWSDt-zH42QNy2JeMaAzXL2-0MUGX-ZiGfIafDn-pk8QaqyRjuv9Kg~90c9b0e403e0d9ea1c1bb615ab789f6a

Analysts' recommendations: Palvella Therapeutics, Inc.

08:24pm	Oppenheimer Adjusts Palvella Therapeutics Price Target to $232 From $210, Maintains Outperform Rating	MT
10-16	William Blair Initiates Coverage on Palvella Therapeutics With Outperform Rating	MT
05-12	Stephens Initiates Coverage on Palvella Therapeutics With Overweight Rating, $220 Price Target	MT
05-08	Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating	MT
04-01	Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating	MT
02-25	Chardan Raises Price Target on Palvella Therapeutics to $210 From $174, Keeps Buy Rating	MT
02-24	Mizuho Adjusts Price Target on Palvella Therapeutics to $250 From $205, Maintains Outperform Rating	MT
01-07	Mizuho Initiates Palvella Therapeutics at Outperform, Price Target is $205	MT
01-07	Mizuho Initiates Palvella Therapeutics at Outperform	MT
12-16	Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating	MT
12-05	BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target	MT
11-11	Palvella Therapeutics reports third quarter 2025 financial results and provides corporate update	RE
26/09/25	Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating	MT
09/09/25	Oppenheimer Initiates Palvella Therapeutics at Outperform	MT
15/08/25	Chardan Adjusts Price Target on Palvella Therapeutics to $60 From $50, Maintains Buy Rating	MT
06/08/25	Raymond James Initiates Palvella Therapeutics at Outperform	MT
21/07/25	Truist Securities Initiates Coverage on Palvella Therapeutics With Buy Rating, $56 Price Target	MT
09/04/25	Chardan Initiates Palvella Therapeutics at Buy With $50 Price Target	MT
26/03/25	Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target	MT
20/02/25	Canaccord Genuity Initiates Palvella Therapeutics at Buy With $39 Price Target	MT
05/02/25	TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target	MT
26/12/24	HC Wainwright Initiates Palvella Therapeutics With Buy Rating, $38 Price Target	MT
18/12/24	Cantor Fitzgerald Initiates Coverage on Palvella Therapeutics With Overweight Rating, $30 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PALVELLA THERAPEUTICS, INC.					+45.62%
	WUXI APPTEC CO., LTD.					+31%
	ARGENX SE					+22.4%
	LONZA GROUP AG					+4.89%
	IQVIA HOLDINGS INC.					+17.75%
	BEONE MEDICINES AG					+12.99%
	REVOLUTION MEDICINES, INC.					+45.7%
	CELLTRION, INC.					+27.37%
	GENMAB A/S					+10.13%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.84%
	Average					+24.17%
	Weighted average by Cap.					+21.73%